BPC-157 vs TB-500: Comparing the Indexed Record
BPC-157 and TB-500 are routinely cross-referenced by researchers scoping a literature review. The two records are not equivalent.
Compound profiles
BPC-157 in the indexed record
Searching BPC-157 against the PubMed index returns 228 records, a moderate evidence base, alongside 4 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Altern Ther Health Med, Cell Tissue Res, Curr Rev Musculoskelet Med, spanning 2019–2025.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain — Altern Ther Health Med, 2021. PMID: 34324435
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — HSS J, 2025. PMID: 40756949
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Cell Tissue Res, 2019. PMID: 30915550
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review — Pharmaceuticals (Basel), 2025. PMID: 40005999
TB-500 in the indexed record
Indexed output for TB-500 stands at 26 records, a limited literature, alongside 1 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Am J Sports Med, Front Aging, J Am Acad Orthop Surg Glob Res Rev, spanning 2024–2026.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro — J Chromatogr B Analyt Technol Biomed Life Sci, 2024. PMID: 38382158
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine — Am J Sports Med, 2026. PMID: 42578445
Side-by-side research profile
| Parameter | BPC-157 | TB-500 |
|---|---|---|
| PubMed indexed records | 228 | 26 |
| Registered studies (ClinicalTrials.gov) | 4 | 1 |
| Literature depth | Moderate | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
BPC-157 and TB-500 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for BPC-157 describes conditions validated for BPC-157: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to TB-500 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
How the literature differs
The indexed record is not symmetrical between these two compounds. BPC-157 carries 202 more indexed records than TB-500, which means published methodology, characterisation data and replication attempts are more readily located for BPC-157. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (4 vs 1) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
What the paperwork has to show
A certificate of analysis is only meaningful when it names the lot printed on the vial. Purity by HPLC and identity by mass spectrometry answer two different questions, and a document reporting one is not evidence of the other.
Frequently asked questions
Which of BPC-157 or TB-500 has more published research?
BPC-157, with 228 indexed PubMed records against 26.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Are BPC-157 and TB-500 the same compound?
No. They are structurally distinct research compounds with separate literature records — 228 indexed records for BPC-157 and 26 for TB-500.
Related references
- BPC-157 — product and lot documentation
- TB-500 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.